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Abstract
Background: Patients with a left ventricular ejection fraction (LVEF) of less than 40 % are at high risk of developing
postoperative low cardiac output syndrome (LCOS). Despite actual treatments (inotropic agents and/or mechanical
assist devices), the mortality rate of such patients remains very high (13 to 24 %). The LICORN trial aims at assessing
the efficacy of a preoperative infusion of levosimendan in reducing postoperative LCOS in patients with poor LVEF
undergoing coronary artery bypass grafting (CABG).
Methods/Design: LICORN study is a multicenter, randomized double-blind, placebo-controlled trial in parallel groups.
340 patients with LVEF ≤40 %, undergoing CABG will be recruited from 13 French hospitals. The study drug will be
started after anaesthesia induction and infused over 24 h (0.1 μg/kg/min).
The primary outcome (postoperative LCOS) is evaluated using a composite criterion composed of: 1) need for
inotropic agents beyond 24 h following discontinuation of the study drug; 2) need for post-operative mechanical assist
devices or failure to wean from these techniques when inserted pre-operatively; 3) need for renal replacement therapy.
Secondary outcomes include: 1) mortality at Day 28 and Day 180; 2) each item of the composite criterion of the
primary outcome; 3) the number of “ventilator-free” days and “out of intensive care unit” days at Day 28.
Discussion: The usefulness of levosimendan in the perioperative period has not yet been documented with a high
level of evidence. The LICORN study is the first randomized controlled trial evaluating the clinical value of preoperative
levosimendan in high risk cardiac surgical patients undergoing CABG.
Trial registration number: NCT02184819 (ClinicalTrials.gov).
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Background
Patients with an ejection fraction of less than 40 % are at
high risk of developing postoperative low cardiac output
syndrome (LCOS) following cardiac surgery. The pa-
tients who develop this condition exhibit a very high
mortality rate, ranging between 13 to 24 %, whereas
those who are not affected by this complication have a
mortality of 2 % only [1]. The LCOS is also associated
with more frequent complications including pulmonary
impairment, myocardial infarction, stroke, renal failure,
and need for reoperation [2, 3]. Preventing LCOS is there-
fore a priority for anaesthesiologists working with cardiac
surgical patients. The incidence of LCOS following coron-
ary artery bypass grafting (CABG) surgery varies from 3 to
14 % [1], but the presence of a preoperative left ventricular
dysfunction (i.e.: 20 % < left ventricular ejection fraction
(LVEF) < 40 %) doubles the risk [1].
The therapeutic management of LCOS usually involves
inotropic agents (catecholamines, phosphodiesterase in-
hibitors) as first-line treatment. Catecholamines may
worsen myocardial oxygen imbalance and have been asso-
ciated with an increase in morbidity and mortality after
cardiac surgery [4]. Phosphodiesterase inhibitors such as
milrinone are also associated with deleterious side-effects,
such as hypotension and arrhythmia, and increased mor-
tality in heart failure patients [4, 5]. New drugs that could
help for the management of LCOS with a better tolerance
profile are therefore highly desirable, in particular in view
of the changing demographic profile of cardiac surgical
patients whose severity at admission has steadily increased
over the past years.
Levosimendan acts as an inotrope and a vasodilator via
two different pathways. First, it induces a calcium-
dependent binding to troponin C resulting in a
“sensitization” of the myofilaments to calcium and a positive
inotropic effect, without impairing myocardial oxygen bal-
ance. Second, it opens smooth muscle ATP-dependent po-
tassium (KATP) channels, thereby producing a vasodilatation.
In addition, levosimendan also opens the mitochondrial
KATP channels, an action that has been linked to a cardio-
protective effect [6].
Several studies have suggested that levosimendan
could be helpful to prevent LCOS and reduce morbidity
and mortality after cardiac surgery [7–10]. Two recent
meta-analyses on the perioperative use of levosimendan
reinforce the idea of a potential benefit on outcomes,
especially in patients with poor preoperative left ven-
tricular ejection fraction [11, 12]. They also conclude
that a large prospective randomized trial should be per-
formed to confirm this hypothesis. The purpose of the
“Levosimendan in coronary artery revascularization”
(LICORN) trial is to verify the ability of levosimendan to




We target the recruitment of patients aged over 18,
scheduled for CABG surgery with cardiopulmonary by-
pass, who have a LVEF equal to, or less than 40 %, re-
gardless of the method of assessment. The CABG may
be combined (or not) with the repair of a valve or of an-
other cardiac structure. The patients can be enrolled
even if they receive preoperative inotropes, or if the sur-
geon decides to insert an intra-aortic balloon pump
(IABP) prior to cardiopulmonary bypass, or if they have
another left ventricular assist device in place. The exclu-
sion criteria are listed in Table 1.
Study design
Thirteen cardiac surgical centers, including 12 University
hospitals and 1 private hospital, have been invited to par-
ticipate in the study. The study is a randomized, double-
blind, two-arm parallel-group, placebo-controlled phase
III study. The chronology of the protocol is depicted in
the Figure. Patients will be followed until postoperative
day 180.
Study drug administration
The study drugs are stored at 2–8 °C until reconstitution
using 500 ml of 5 % dextrose solution, immediately prior
to patient administration. Physical and chemical stability
of the preparation at room temperature is demonstrated
up to 24 h following reconstitution [13]. The placebo is
made of riboflavin in order to reproduce the yellow
colour of levosimendan. No bolus is administered. A
continuous infusion of 0.1 μg/kg/min is started just after
anaesthesia induction and is administered over the ensu-
ing 24 h in the absence of serious adverse reaction.
Tables are provided to clinicians to determine the flow
Table 1 Exclusion criteria
Preoperative renal failure (creatinine clearance < 30 ml/min)
Liver failure (prothrombine time < 50 %, in the absence of vitamin K
antagonist
Cardiac surgery without CABG
Pregnancy
Emergency surgery, defined as surgery within the 24 h of the operative
indication
Known allergy to levosimendan
Severe hypotension prior to surgery (mean arterial pressure < 60 mmHg)
Severe tachycardia prior to surgery (heart rate > 120 bpm)
Prior history of torsade de pointe
Dynamic obstruction of the left ventricular outflow tract
Lack of signed informed consent
Lack of affiliation to social security
Patient already involved in another trial
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rate of the drug solution according to patient’s weight.
The study drug administration is discontinued in case of
serious adverse events such as: 1) anaphylactic reaction,
2) refractory hypotension defined as a mean arterial
pressure (MAP) < 60 mmHg despite optimal therapeutic
response comprising fluids and vasoconstrictors at the
discretion of the clinician, 3) intractable arrhythmia.
Randomization and blinding procedures
The allocation of treatments will be performed by
minimization (deterministic dynamic allocation) [14]. The
procedure will take into account the center, the surgery
performed (CABG alone, or combined surgery), LVEF
(<30 %, or between 30 and 40 %), the redo nature of the
surgery, the existence of a treatment by preoperative ino-
tropic agents or IABP, and the existence of preoperative
beta-blocker therapy. It will balance the distribution of
prognostic factors between the two groups and within
each center. We will introduce a random component to
reduce the predictability of the allocation.
We chose to use a minimization procedure because the
stratified randomization is not effective in trials with small
sample size and large number of strata. This is the case in
the present study since the 3 factors that must be con-
trolled (type of surgery, preoperative treatment, and LVEF
range) would result in eight strata at all 13 centers.
The randomization algorithm will be established by an
independent statistician. This algorithm will then be in-
stalled on a website with secure access. At randomization,
the clinician will obtain the blinded patient allocation num-
ber after having provided the patient characteristics re-
quired by the algorithm. The result of the randomization
will be sent to the pharmacy at the center involved.
Outcome measures
The primary aim of the trial is to demonstrate that
levosimendan administration at the time of anaesthe-
sia induction in patients undergoing CABG (alone, or
combined with other cardiac repair) with poor LV
function (LVEF ≤ 40 %) can reduce the incidence and
severity of postoperative LCOS. Our primary endpoint
is a composite of three elements that reflect this
syndrome:
1) The need for inotropic agents beyond 48 h after the
initiation of the study treatment infusion;
2) The need for post-operative circulatory mechanical
assist devices (intra-aortic balloon pump, extra-
corporeal life support, left ventricular assist device
such as the Impella® pump) or failure to wean from
these techniques (at 96 h following initiation of the
study treatment) if they were inserted pre-operatively;
3) The need for renal replacement therapy (RRT) at
any time during Intensive care unit stay (ICU).
The secondary goals are: 1) to compare mortality
among placebo and levosimendan patients, and 2) to
evaluate the effects of levosimendan treatment on ICU
and hospital length of stay, as well as its impact on the
duration of ventilation, and on each component of the
primary composite endpoint separately. Thus, the
secondary endpoints include:
1) Mortality at Day 28 and Day 180 (safety issue)
2) Individual components of the primary endpoint
mentioned above
3) Number of days with mechanical circulatory assist
devices
4) Number of days with renal replacement therapy and
number of RRT kits that are used for each patient.
5) Number of ventilator-free days and out-of-ICU days
at Day 28.
Data collection
After enrolment into the study, patients are assigned a
unique subject number associated with their initials.
Data are collected by investigators with the help of clin-
ical research assistants and recorded on paper case re-
port forms (CRF). A CRF must be completed for each
participant. The data entered into each CRF will be
assessed by sponsor representatives, according to good
clinical practices. In addition to the patient’s medical file,
the investigator agrees to complete the documents re-
lated to treatment management provided by the sponsor
and the CRF at each step of the protocol (Fig. 1). All
corrections and alterations of data on the CRF must be
made by the investigator him/herself and highlighted ac-
cording to predefined instructions. The data manage-
ment will be carried out by the Clinical Research Unit of
Hôpital Européen Georges Pompidou. A list of variables
of interest will be developed with an Operational Data
Model format by the study primary investigator and the
study statistician. This list will allow the implementation
of the case report form and of the database. A data-
management plan, developed jointly by the study
coordinator, the data-manager, and the statistician will
be implemented. After correcting for potential errors de-
tected by this plan, a data review meeting will be held to
validate the entire database with the study coordinator.
The database will then be frozen prior to statistical ana-
lysis. The data will be analysed using SAS software (SAS
Institute Inc., Cary, NC).
Statistics
Number of subjects required
The number of subjects required is 340 patients (170
per group). This sample size has been obtained using the
Nquery Advisor statistical software according to the fol-
lowing assumptions:
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(1)Incidence of the composite endpoint in the control
group 65 % (proportion estimated from our personal
data);
(2)Incidence of the composite endpoint in the
levosimendan group 50 %. According to Levin et al.
[15], postoperative administration of levosimendan
in patients having a LCOS has reduced by 28 % the
use of an additional inotropic drug and by 12 % the
use of a mechanical assist device, compared to
dobutamine.
(3)Alpha risk of 5 % and power of 80 %.
Statistical analysis
The results will be presented in accordance with the
CONSORT 2010 recommendations. Estimates of the
primary and secondary endpoints incidence will be pro-
vided with their 95 % confidence interval.
The primary analysis will be done on an intention to
treat basis, in all patients included in the trial and having
undergone randomization.
Incidence of the unadjusted composite endpoint will
be compared between the two groups using a Chi-
square test. A multiple logistic regression model will
compare the effects adjusted for LCOS prognostic fac-
tors: type of surgery performed (CABG alone, or com-
bined surgery), LVEF (<30 %, or between 30 and 40 %),
redo nature of the surgery, preoperative treatment with
inotropic drugs or mechanical assist device and presence
of preoperative beta-blocker therapy.
Three subgroups analyses are planned. They will assess
whether the levosimendan effect varies according to:
 Type of surgical procedure performed (CABG alone
or combined surgery)
 LVEF <30 %, or 30 % ≤ LVEF ≤ 40 %
 Presence of a preoperative treatment with beta-
blockers.
The heterogeneity of the treatment effect will be eval-
uated by an interaction test and presented using a forest
plot [16].
Discussion
Rationale for levosimendan in cardiac surgical patients
with poor LV function
Levosimendan was introduced a few years ago and was ini-
tially approved in some countries for the management of
acutely decompensated heart failure following the results of
two multicenter randomized controlled trials (LIDO and
SURVIVE) [17, 18]. Preliminary data on the beneficial
effects of levosimendan in cardiac surgical patients has
been reported in several studies [7–9, 15, 19–24]. However,
this data was obtained from trials conducted at single
centers [8, 19–24], on small cohorts (<100 patients) [8, 9,
20–22, 24], without randomization [24], or according to a
single-blinded protocol [7, 9, 15, 22–24]. Therefore, the
level of evidence supporting the beneficial effect of levosi-
mendan is not very strong.
In a small randomized study, patients with a preopera-
tive LVEF ≤30 % treated with levosimendan received a
smaller amount of dobutamine in comparison to those
treated with milrinone and had a lower mortality rate
after surgery [9]. In another prospective, randomized,
double-blind study comparing levosimendan to a pla-
cebo in 60 patients with a preoperative LVEF <50 %
undergoing CABG, levosimendan was found to enhance
primary weaning from cardiopulmonary bypass in com-
parison to the placebo [8]. Levin et al. compared
Fig. 1 Schematic representation of the different steps of the LICORN protocol. LVEF: left ventricular ejection fraction; CABG: coronary artery
bypass grafting; RRT: renal replacement therapy; ICU: intensive care unit
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preoperative levosimendan versus placebo in 252 CABG
patients with a LVEF <25 % and found that levosimen-
dan reduced mortality (3.9 vs 12.8 %; p < 0.05), the inci-
dence of LCOS (7.1 vs 20.8 %; p < 0.05) and of
complicated weaning from cardiac pulmonary bypass
(2.4 vs 9.6 %; p < 0.05). Compared to the placebo
group, the levosimendan-treated patients also required
less inotropes (7.9 vs 58.4 %; p < 0.05), vasopressors
(14.2 vs 45.6 %; p < 0.05), and intra-aortic balloon
pumping (6.3 vs 30.4 %; p < 0.05) [7]. A recent meta-
analysis of perioperative use of levosimendan con-
firmed that the efficacy of levosimendan seems to be
more pronounced in patients with preoperative left
ventricular dysfunction [12].
Study population
In addition to CABG surgery, we deliberately choose to
enrol patients undergoing combined surgery despite the
fact that they might introduce some variability in our
population. Indeed, a patient with aortic stenosis and
poor left ventricular function associated with coronary
artery disease is likely to have a myocardial dysfunction
related to the long lasting pressure overload in addition
to myocardial ischemia. Ischemic mitral insufficiency
combines chronic volume overload and ischemia, and
the correction of mitral regurgitation (valve repair or re-
placement) will adversely affect left ventricular afterload.
Furthermore, these combined procedures are inherently
associated with longer aortic cross-clamping times
which, in turn, may increase the probability of a LCOS,
as reflected by the higher mortality rate in this popula-
tion [25]. We have no data to determine whether levosi-
mendan is more likely to have beneficial effects in one
subgroup or another. The cardio protective effect of
mitochondrial KATP channel opening might be more ef-
fective in patients with pure ischemic cardiomyopathy.
But the vasodilatation resulting from vascular smooth
muscle KATP channel opening and the inotropic effect
due to calcium sensitizing of the myofilaments are ex-
pected to be beneficial regardless of the mechanism of
LV failure. The respective importance of each pharmaco-
logic effect of levosimendan is not clearly identified. The
minimization process used for randomization takes into
account the fact that CABG is isolated or combined with
a valve repair and should help in addressing this ques-
tion of the efficacy of the drug in relation to the under-
lying type of pathology. Another reason for being “less
selective” is to facilitate recruitment and to maximize
the number of eligible patients over a relatively short
period of time. This is an important issue as levosimen-
dan must be used within 24 months after production.
Broadening of inclusion criteria is also likely to generate
outcome data more reliably representative of current
practice in the “real world”.
Pharmacokinetics of levosimendan
Levosimendan has a linear pharmacokinetic profile with
an elimination half-life of about one hour. Maximum
plasma levosimendan concentration is reached 4.4 h
after an infusion of 0.2 μg/kg/min over 6 h. Maximum
plasma concentration of its main metabolite (OR-1896)
is reached 2–5 days after an infusion of 0.2 μg/kg/min
over 24 h. Since OR-1896 has a similar haemodynamic
profile to levosimendan itself, this explains the pro-
longed effect of the drug. Levosimendan is extensively
metabolized by the liver and inactive metabolites are ex-
creted in the urine and the faeces within 24 h [26]. For
patients with renal impairment, defined as a glomerular
filtration rate between 30 and 60 mL/min/1.73 m2, the
dose of levosimendan does not need to be reduced and
the drug even seems to improve kidney function in
patients with acute decompensated heart failure [27].
Interestingly, the beneficial haemodynamic effects of
levosimendan, unlike those of dobutamine, are not at-
tenuated by the concomitant use of β-blockers [18].
Side effects of levosimendan and safety issues
According to the clinical data of REVIVE II and SUR-
VIVE trials, moderate hypotension (mean reduction in
systolic blood pressure: −4 mmHg, and diastolic blood
pressure: − 6 mmHg) was the most frequent adverse
event observed after a bolus infusion of levosimendan
(12 μg/kg) and lasted for 12 h [17, 28]. In the SURVIVE
trial, the occurrence of hypotension did not differ be-
tween the levosimendan and dobutamine groups. How-
ever, based on this finding we will not administer any
bolus of levosimendan in our patients in order to reduce
the risk of intra-operative hypotension. Previous authors
using a continuous infusion of levosimendan without a
loading dose observed beneficial effects without
hypotension [9, 22, 24]. Moreover, 2012 European
Society of Cardiology guidelines for the diagnosis and
treatment of acute and chronic heart failure recom-
mended the use of levosimendan without a loading dose
for hypotensive patients [29].
Levosimendan administration has also been associated
with a higher incidence of atrial fibrillation in comparison
to a placebo (9 vs 2 %) [28] or dobutamine (9 vs 6 %) [17]
in trials involving patients with left ventricular failure. In
contrast, meta-analysis of studies involving surgical pa-
tients suggested a reduced incidence of atrial fibrillation in
the group of patients treated with levosimendan [30]. We
will collect information on the incidence of atrial fibrilla-
tion in our patients to try to provide new insight regarding
these discrepant results. Atrial fibrillation detection will
rely on continuous electrocardiography monitoring while
in ICU, and on clinically patent arrhythmia episodes
leading to 12-lead electrocardiography recording while in
the ward. Information regarding other arrhythmias
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(ventricular tachycardia, ventricular fibrillation, torsade de
pointe) will also be collected to assess the safety profile of
levosimendan in the perioperative period.
Perioperative ischemia is a major concern after CABG
surgery. The safety profile of levosimendan regarding
the myocardial oxygen balance seems favourable in com-
parison to dobutamine. Previous studies involving
CABG patients suggested that postoperative ischemia
was less frequent in levosimendan-treated patients with
respect to a placebo [7, 19]. Peak postoperative troponin
I (between Day 1 and Day 2), measured by highly-
sensitive troponin assay will be monitored at each center
to assess myocardial damage [31].
Conclusion
This trial is intended to answer an important question:
is there a role for levosimendan as a pre-treatment for
patients with poor left ventricular function (LVEF
≤40 %) undergoing CABG (alone or combined with valve
surgery) under cardiopulmonary bypass? The primary
objective of the study is to quantify the occurrence of
simple clinical markers of low cardiac output syndrome
in the levosimendan and placebo groups. If levosimen-
dan proves superior to a placebo, this will result in a
change of management for high risk cardiac surgical pa-
tients, which is clinically relevant in view of the in-
creased prevalence of this patient cohort.
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